Clonidine
| Clinical data | |
|---|---|
| Pronunciation | /ˈklɒnədiːn/ |
| Trade names | Catapres, Kapvay, others |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a682243 |
| License data | |
| Pregnancy category |
|
| Dependence liability | Psychological: Low Physical: High |
| Routes of administration | Oral, epidural, intravenous, transdermal, topical |
| Drug class | • α2-Adrenergic receptor agonist
• Imidazoline receptor agonists |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | 70–80% (oral), 60–70% (transdermal) |
| Protein binding | 20–40% |
| Metabolism | Liver to inactive metabolites, 2/3 CYP2D6 |
| Onset of action | IR: 30–60 minutes after an oral dose |
| Elimination half-life | IR: 12–16 hours; 41 hours in kidney failure, 48 hours for repeated dosing |
| Duration of action | 4–8 hours |
| Excretion | Urine (72%) |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.021.928 |
| Chemical and physical data | |
| Formula | C9H9Cl2N3 |
| Molar mass | 230.09 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Clonidine, sold under the brand names Catapres and Kapvay, among others, is an α2-adrenergic receptor agonist, hypotensive, sedative and anxiolytic drug used to treat high blood pressure, attention deficit hyperactivity disorder, perioperative pain, drug withdrawal (e.g., alcohol, opioids, or nicotine), and menopausal flushing. Clonidine is sometimes prescribed off-label for tics. It is used orally (by mouth), by injection, or as a transdermal skin patch. Onset of action is typically within an hour with the effects on blood pressure lasting for up to eight hours. Xylazine is a structural analog of clonidine.
Common side effects include dry mouth, dizziness, headaches, hypotension, and sleepiness. Severe side effects may include hallucinations, heart arrhythmias, and confusion. If rapidly stopped, withdrawal effects may occur, such as a dangerous rise in blood pressure. Use during pregnancy or breastfeeding is not recommended. Clonidine lowers blood pressure by stimulating α2-adrenergic receptors and imidazoline receptors in the brain, which results in relaxation of many arteries.
Clonidine was patented in 1961 and came into medical use in 1966. It is available as a generic medication. In 2023, it was the 82nd most commonly prescribed medication in the United States, with more than 8 million prescriptions.